A prospective progeria drug revs up cellular autophagy and clears tau in neurons derived from patients with frontotemporal dementia. In mouse models, the drug rescues abnormal behavior.
Women who started menstruation after the age of 16, and/or entered menopause before 47, had higher rates of dementia later in life.
Experts said Phase 3 data did not prove the device could slow AD.
Using rigorous tissue-processing techniques, researchers find thousands of newborn neurons in older human hippocampi, but a dearth in brains with AD pathology.
Analysis of 19 H1 MAPT subhaplotypes ties five to progressive supranuclear palsy.
Award recognizes his contributions to basic and clinical research.
Among 20 focus areas, 47 research recommendations cover the gamut from basic science to health disparities.
From central IRBs, certified raters, to local transport: Changes large and small are needed to ramp up drug testing in Alzheimer’s.
In Year Three, GAP Trial Network Is Starting to Hum Getting to Go: GAP-Net Sets Sight on Faster Start Three years after the Global Alzheimer’s Platform (GAP) Foundation launched GAP-Net, a standing network of clinical trial sites optimized for Alzheimer’s ...
With three trials and initiatives to boost recruitment, GAP-Net is gaining some traction in the field.
Atomic resolution structures of tau filaments from three people with CTE revealed a common strain of tau induced by chronic head injuries.
Futility analysis predicts failure to reach primary endpoint.
Perturbations in the hormone correlate with memory problems. But does FGF23 act in the brain, or affect cognition indirectly via the kidneys?
Exposing AD mice to multisensory gamma therapy induced 40-Hz waves in their brains, plus effects on amyloid, tau, microglia, blood vessels, and cognitive function.
Among British civil servants, the quality of their diet did not correlate with their risk of developing dementia cognitive decline over 25 years.
No filters selected